Affichage 101 à 102 des 102 essais cliniques
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|
ESSAIS CLINIQUES No essai ClinicalTrials.gov ID |
Phase | Coordonnateur(rice) | |
|---|---|---|---|
|
(EN) A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
ASCENT-04 NCT05382286  Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Wagdy Rezk 514-340-8222 poste 28248 |
|
|
(EN) Sentinel Node Biopsy and Targeted Axillary Dissection in Node-Positive Breast Cancer Patients With Clinically Negative Axilla
TADEN NCT04671511 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Joelle-Marie Poirier 514-340-8222 poste 23766 |
Groupe d'étude en oncologie du Québec